|We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.|
Not to hype a stock here lol, but one stock to keep an eye on over the short term is MBRX trading under $3. When trials begin on Annamycin for the treatment of Leukemia in around the next 45 days, you would think MBRX would trade in the $15 - $20 level "to start" as similar companies are now. Could be one to hold for awhile. This drug is crucial for treating leukemia patients in receiving a bone marrow transplant, which is usually required for survival. That drug by MBRX is drastically needed. Leukemia is a monster, and I know first hand. Always do your own research though!
Also important to note -- similar pharma stocks with a lot let promise are currently trading in the $12 - $20 range, and MBRX stock is so volatile, that they've even had to pause trading, lol. It's extremely explosive with a very high upside. Could be one to ride out.
Best of luck to all!
|© 2022 Knight Sac Media. Data provided by IEX, Alpha Vantage, Coinbase, Binance, Fintel and CityFALCON News|